Search
Amaranthus retroflexus pollen
go.drugbank.com/drugs/DB10381ApprovedAmaranthus retroflexus pollen is the pollen of the Amaranthus retroflexus plant. Amaranthus retroflexus pollen is mainly used in allergenic testing.
Mixtures: Number Four Weed MixtureLC16M8
go.drugbank.com/drugs/DB05019InvestigationalLC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines. It is the only attenuated vaccine to be licensed for use in ...
Potassium metabisulfite
go.drugbank.com/drugs/DB15841InvestigationalMixtures: PROCALAMINE SISE 1000 ML(SETLI), PROCALAMINE SISE 500 ML(SETLI)Ethinylestradiol
go.drugbank.com/drugs/DB00977ApprovedInvestigationalEthinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was developed in an effort to create an estrogen with greater oral bioavailability. These properties were achieved by the substitu...
Mixtures: Diane mite - Dragees, Yris mite 0,075 mg/0,02 mg DrageesPoloxamer 407
go.drugbank.com/drugs/DB11252InvestigationalIt consists of a central hydrophobic block of polypropylene glycol that is flanked on each side by polyethylene glycol blocks, both hydrophilic in nature.
Thimerosal
go.drugbank.com/drugs/DB11590ApprovedThiomersal (INN), commonly known in the U.S. as thimerosal, is an organomercury compound. This compound is a well-established and widely used antiseptic and antifungal agent. Developed in 1927, thimerosal has been and is still being used...
Ecallantide
go.drugbank.com/drugs/DB05311ApprovedEcallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema. Ecallantide is a recombinant 60-amino-acid protein produced in Pichia pastoris yeast cells ...
Doripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnDoripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical t...
Fruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigational[A262097] For the small-molecule approach, most earlier generations of VEGFR inhibitors such as [sunitinib], [sorafenib], [regorafenib], and [pazopanib] have poor selectivity, thus increasing the risk